Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
    • Supplements
    • Publish Supplement
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in
  • My Cart

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • My Cart
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
    • Supplements
    • Publish Supplement
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers

Discover Pediatric Collections on COVID-19 and Racism and Its Effects on Pediatric Health

American Academy of Pediatrics
Article

Comparative Efficacy of the Lederle/Takeda Acellular Pertussis Component DTP (DTaP) Vaccine and Lederle Whole-Cell Component DTP Vaccine in German Children After Household Exposure

Ulrich Heininger, James D. Cherry, Klemens Stehr, Sabina Schmitt-Grohé, Michael Überall, Suzanne Laussucq, Thomas Eckhardt, Martin Meyer, Jeffrey Gornbein and the Pertussis Vaccine Study Group
Pediatrics September 1998, 102 (3) 546-553; DOI: https://doi.org/10.1542/peds.102.3.546
Ulrich Heininger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James D. Cherry
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klemens Stehr
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabina Schmitt-Grohé
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Überall
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suzanne Laussucq
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Eckhardt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Meyer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Gornbein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • Comments
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Download PDF

Abstract

Background. A household contact substudy was performed as part of a prospective, cohort pertussis vaccine efficacy trial in Germany.

Design. Infants received four doses of either the Lederle/Takeda acellular pertussis component diphtheria-tetanus toxoids (DTP) vaccine (DTaP) or Lederle whole-cell component DTP vaccine at 3, 4.5, 6, and 15 to 18 months of age (Wyeth-Lederle Vaccines and Pediatrics, Pearl River, NY). An open control group received three doses of diphtheria and tetanus toxoids vaccine (DT) at 3, 4.5, and 15 to 18 months of age. Vaccine efficacy rates were calculated using a number of principal and ancillary case definitions for primary, secondary, and noncases by analyzing secondary attack rates in study infants after exposure to pertussis in the household using 7- to 28- and 7- to 42-day postexposure observation periods and the inclusion and the exclusion of noncases who received macrolide antibiotics or trimethoprim-sulfamethoxazole during the exposure period.

Results. During a 3.5-year study period, 10 271 infants (DTP or DTaP, n = 8532; DT, n = 1739) were enrolled and actively followed along with all household members for cough illnesses. Depending on the case definition, 160 to 519 household exposures to pertussis were identified. In general, secondary attack rates in DT recipients were low and this was primarily because of the frequent use of antimicrobial prophylaxis. Using the principal case definitions and the exclusion of noncases who received macrolide antibiotics or trimethoprim-sulfamethoxazole during the exposure period and the 7- to 42-day observation period, the efficacy of DTP against cough illness of ≥7 days duration caused by Bordetella pertussis was 84% (95% confidence interval [CI] = 65–93) and that of DTaP was 58% (95% CI = 30–75). Using similar criteria, the efficacy against typical pertussis (≥21 days of cough with either paroxysms, whoop, or posttussive vomiting) was 94% (95% CI = 77–99) and 86% (95% CI = 62–95) for DTP and DTaP, respectively. The efficacy against any cough illness (with or without) laboratory confirmation was 54% (95% CI = 32–69) and 38% (95% CI = 13–56) for DTP and DTaP, respectively.

Conclusion. This household contact substudy within our cohort study, with active investigator-generated surveillance, was a severe test of vaccine efficacy. Both vaccines (DTP and DTaP) are better at preventing typical pertussis than mild illness. When case definitions similar to those in other recent trials are used, the Lederle/Takeda vaccine has an efficacy similar to other multicomponent DTaP vaccines.

  • Bordetella pertussis
  • acellular pertussis vaccine
  • whole cell pertussis vaccine
  • household contact
  • vaccine efficacy
  • Received December 30, 1997.
  • Accepted March 2, 1998.
  • Copyright © 1998 American Academy of Pediatrics

Individual Login

Log in
You will be redirected to aap.org to login or to create your account.

Institutional Login

via Institution

You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.

Log in through your institution

If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

Offer Reprints

PreviousNext
Back to top

Advertising Disclaimer »

In this issue

Pediatrics
Vol. 102, Issue 3
1 Sep 1998
  • Table of Contents
  • Index by author
View this article with LENS
PreviousNext
Email Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comparative Efficacy of the Lederle/Takeda Acellular Pertussis Component DTP (DTaP) Vaccine and Lederle Whole-Cell Component DTP Vaccine in German Children After Household Exposure
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Request Permissions
Article Alerts
Log in
You will be redirected to aap.org to login or to create your account.
Or Sign In to Email Alerts with your Email Address
Citation Tools
Comparative Efficacy of the Lederle/Takeda Acellular Pertussis Component DTP (DTaP) Vaccine and Lederle Whole-Cell Component DTP Vaccine in German Children After Household Exposure
Ulrich Heininger, James D. Cherry, Klemens Stehr, Sabina Schmitt-Grohé, Michael Überall, Suzanne Laussucq, Thomas Eckhardt, Martin Meyer, Jeffrey Gornbein, the Pertussis Vaccine Study Group
Pediatrics Sep 1998, 102 (3) 546-553; DOI: 10.1542/peds.102.3.546

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Comparative Efficacy of the Lederle/Takeda Acellular Pertussis Component DTP (DTaP) Vaccine and Lederle Whole-Cell Component DTP Vaccine in German Children After Household Exposure
Ulrich Heininger, James D. Cherry, Klemens Stehr, Sabina Schmitt-Grohé, Michael Überall, Suzanne Laussucq, Thomas Eckhardt, Martin Meyer, Jeffrey Gornbein, the Pertussis Vaccine Study Group
Pediatrics Sep 1998, 102 (3) 546-553; DOI: 10.1542/peds.102.3.546
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Print
Download PDF
Insight Alerts
  • Table of Contents

Jump to section

  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • Comments

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Toward a new vaccine for pertussis
  • Antibody Response Patterns to Bordetella pertussis Antigens in Vaccinated (Primed) and Unvaccinated (Unprimed) Young Children with Pertussis
  • The O Antigen Enables Bordetella parapertussis To Avoid Bordetella pertussis-Induced Immunity
  • Pertussis Vaccine Effectiveness Among Children 6 to 59 Months of Age in the United States, 1998-2001
  • Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due to Bordetella pertussis and Other Bordetella Subspecies
  • Immunologic and Epidemiologic Experience of Vaccination With a Monocomponent Pertussis Toxoid Vaccine
  • Clinical Validation of a Polymerase Chain Reaction Assay for the Diagnosis of Pertussis by Comparison With Serology, Culture, and Symptoms During a Large Pertussis Vaccine Efficacy Trial
  • The Science and Fiction of Pertussis Vaccines
  • The Effect of Investigator Compliance (Observer Bias) on Calculated Efficacy in a Pertussis Vaccine Trial
  • Google Scholar

More in this TOC Section

  • Clinical Impact of a Diagnostic Gastrointestinal Panel in Children
  • Intrapartum Group B Streptococcal Prophylaxis and Childhood Allergic Disorders
  • Changes in Neurodevelopmental Outcomes From Age 2 to 10 Years for Children Born Extremely Preterm
Show more Article

Similar Articles

Subjects

  • International Child Health
    • International Child Health
  • Infectious Disease
    • Infectious Disease
    • Epidemiology
    • Vaccine/Immunization
  • Journal Info
  • Editorial Board
  • Editorial Policies
  • Overview
  • Licensing Information
  • Authors/Reviewers
  • Author Guidelines
  • Submit My Manuscript
  • Open Access
  • Reviewer Guidelines
  • Librarians
  • Institutional Subscriptions
  • Usage Stats
  • Support
  • Contact Us
  • Subscribe
  • Resources
  • Media Kit
  • About
  • International Access
  • Terms of Use
  • Privacy Statement
  • FAQ
  • AAP.org
  • shopAAP
  • Follow American Academy of Pediatrics on Instagram
  • Visit American Academy of Pediatrics on Facebook
  • Follow American Academy of Pediatrics on Twitter
  • Follow American Academy of Pediatrics on Youtube
  • RSS
American Academy of Pediatrics

© 2021 American Academy of Pediatrics